SINI, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 625
EU - Europa 233
AS - Asia 102
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 964
Nazione #
US - Stati Uniti d'America 621
IT - Italia 95
SE - Svezia 61
SG - Singapore 38
IN - India 29
DE - Germania 23
CN - Cina 20
FI - Finlandia 14
UA - Ucraina 7
RO - Romania 6
BG - Bulgaria 5
GB - Regno Unito 5
ID - Indonesia 5
IE - Irlanda 5
CA - Canada 4
FR - Francia 4
IR - Iran 4
HK - Hong Kong 3
TG - Togo 3
BE - Belgio 2
NL - Olanda 2
CH - Svizzera 1
EE - Estonia 1
EU - Europa 1
IL - Israele 1
JP - Giappone 1
LB - Libano 1
MK - Macedonia 1
RU - Federazione Russa 1
Totale 964
Città #
Fairfield 119
Houston 54
Ashburn 45
Woodbridge 43
Rome 36
Wilmington 35
Cambridge 32
Seattle 32
Chandler 29
Ann Arbor 25
Singapore 25
Dearborn 24
Santa Clara 20
Princeton 15
San Paolo di Civitate 15
Helsinki 9
Lawrence 9
Millbury 9
Plano 9
Beijing 8
Milan 7
Dublin 5
Jakarta 5
San Diego 5
Sofia 5
Andover 4
Norwalk 4
Boston 3
Bremen 3
Fremont 3
Hong Kong 3
Jacksonville 3
Lomé 3
Los Angeles 3
New York 3
Bovisio-Masciago 2
Dallas 2
Ercolano 2
Falkenstein 2
Formello 2
Latina 2
Nanjing 2
Newark 2
Phoenix 2
Redwood City 2
Sacramento 2
Torino 2
Toronto 2
Zanjan 2
Berlin 1
Boardman 1
Brussels 1
Bühl 1
Cadelbosco di Sopra 1
Edinburgh 1
Falls Church 1
Frattamaggiore 1
Frosinone 1
Fuzhou 1
Grafing 1
Guidonia 1
Henderson 1
Jinan 1
Kraainem 1
Levallois-perret 1
Moscow 1
Nürnberg 1
Ottawa 1
Quzhou 1
Shenyang 1
Suzhou 1
Taiyuan 1
Tallinn 1
Tel Aviv 1
Trumbull 1
Uppsala 1
Vigonza 1
Winnipeg 1
Wuhan 1
Totale 710
Nome #
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience 122
Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes 101
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 99
Spontaneous immunogenicity of ribosomal P0 protein in patients with benign and malignant breast lesions and delay of mammary tumor growth in P0-vaccinated mice 95
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab 93
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome 86
Pharmacogenetic assessment of toxicity in patients treated with taxane-based chemotherapy for solid tumors 76
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients. A multicenter Italian experience 70
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 62
null 55
null 48
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 43
Synchronous primary papillary breast cancer, medullary thyroid carcinoma and neuroendocrine tumor in postmenopausal woman 36
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers 24
Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients 15
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study 13
Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice 11
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 7
Totale 1.056
Categoria #
all - tutte 3.094
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.094


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020213 0 0 0 0 0 51 40 33 33 30 16 10
2020/202197 20 6 13 5 2 17 0 4 7 19 0 4
2021/2022143 0 4 15 9 23 7 2 13 7 9 30 24
2022/2023159 37 42 11 10 21 8 10 8 4 0 6 2
2023/202487 8 14 5 12 14 11 0 5 0 7 9 2
2024/2025125 8 9 14 45 30 19 0 0 0 0 0 0
Totale 1.056